postmenopausal from their chemotherapy. So, any effect from ovarian suppression was diluted. What was different about this trial was that we managed to get agreement from all the major academic cooperative groups from around the world to collaborate on the one trial, which is relatively unique..
as to whether adding ovarian function suppression for premenopausal women, who receive adjuvant Tamoxifen, will provide any additional advantage. Premenopausal women, who receive adjuvant chemotherapy, can have their ovaries stop functioning, and the ovaries normally produce jejunum, when t..
the risk of developing breast cancer for the next five years. And that's only used for patients, who older than 35. So, Gail risk model includes the age of the patient, age of menarche, what age they had the first period, age and the first live both, then, of course, how old they are, family histor..